Predicting Clearance with Simple and Permeability-Limited Physiologically Based Pharmacokinetic Frameworks: Comparison of Well-Stirred, Dispersion, and Parallel-Tube Liver Models.

Autor: Nagar S; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania korzekwa@temple.edu swati.nagar@temple.edu., Parise R; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania., Korzekwa K; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania korzekwa@temple.edu swati.nagar@temple.edu.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1060-1072. Date of Electronic Publication: 2024 Sep 16.

First-in-Human Predictions of Hepatic Clearance for Drugs With the Well-Stirred Model: Comparative Assessment Between Models of Fraction Unbound Based Either on the Free Drug Hypothesis, Albumin-Facilitated Hepatic Uptake or Dynamic Binding Kinetics.

Autor: Poulin P; Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Québec, Canada. Electronic address: patrick-poulin@videotron.ca.

Publikováno v: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Aug; Vol. 113 (8), pp. 2641-2650. Date of Electronic Publication: 2024 May 24.

Evaluation and Optimization of a Microcavity Plate-Based Human Hepatocyte Spheroid Model for Predicting Clearance of Slowly Metabolized Drug Candidates.

Autor: Kukla DA; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois., Belair DG; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois., Stresser DM; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois david.stresser@abbvie.com.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jul 16; Vol. 52 (8), pp. 797-812. Date of Electronic Publication: 2024 Jul 16.

Comparison of Human Long-Term Liver Models for Clearance Prediction of Slowly Metabolized Compounds.

Autor: Preiss LC; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Georgi K; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Petersson C; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.) carl.petersson@merckgroup.com.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 May 16; Vol. 52 (6), pp. 539-547. Date of Electronic Publication: 2024 May 16.

Changes in Plasma Clearance of CYP450 Probe Drugs May Not be Specific for Altered In Vivo Enzyme Activity Under (Patho)Physiological Conditions: How to Interpret Findings of Probe Cocktail Studies.

Autor: de Jong LM; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands., van de Kreeke M; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands., Ahmadi M; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Knibbe CAJ; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands., van Hasselt JGC; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands., Manson ML; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands., Krekels EHJ; Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands. E.krekels@lacdr.leidenuniv.nl.; Certara Inc, Princeton, NJ, USA. E.krekels@lacdr.leidenuniv.nl.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Nov; Vol. 63 (11), pp. 1585-1595. Date of Electronic Publication: 2024 Oct 27.